Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immuno-Oncology Attracts Big Deal Dollars For Biotechs

This article was originally published in Start Up

Executive Summary

Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.

You may also be interested in...



An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics

Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.

Likelihood Of Approval Matters When Evaluating A Drug Development Partner

Despite having the lowest average likelihood of approval rating for US FDA regulatory decisions out of 18 disease groups, early-stage oncology deals continue to attract big price tags.

Finance Watch: The Job Cuts Keep Coming As Companies Try To Conserve Cash

Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel